DAEHWA PHARMACEUTICAL CO., LTD. Technology Information No . 1
Indication(적응증) Gastric cancer as 1st indication
New drug(신약) (Ingredients)
IMD(개량신약) (Ingredients) Paclitaxel
Biomedicine (Ingredients)
Etc.
Item description World 1st approved paclitaxel oral solution. This is 1st project of our platform technology DHLASED(DaeHwa Lipid-bAsed SelfEmulsifying Drug Delivery) technology. No need premedication, and same effect to IV form of paclitaxel, but much safer (Especially lower alopecia, peripheral neuropathy)
Development status Approved by MFDS(Korean FDA) on Sep. of 2016 through Clincal trial I~III. Furthermore, we’ve built up dedicated facilities for this LIPORAXEL (Lipid Oral Paclitaxel).
Plans for Out-Licensing or joint R&D or investment We are looking for licensee for overseas market.
Patent Well protected by PCT patent until 2034 (Separately enrolled patent to 11countries)
2
Dimentia
Natural extract
Item description It is natural drug, our code name DHP1401. Confirming efficacy of memory improvement on dementia model.
Development status Safety establishment through toxicity test and clinical trial II IND was approved by MFDS on Aug. 2015
Plans for Out-Licensing or joint R&D or investment We are looking for partner as co-developer.
Patent Domestic patent 2 + Overseas 8